The NIDA P30 Core Center, entitled ?Center on Intersystem Regulation by Drugs of Abuse?, provides outstanding scientific expertise and resources to NIH investigators in order to advance research productivity and innovations in addiction research. The Center has proven to be a catalyst for interdisciplinary studies and has created synergy between investigators from diverse disciplines. The major themes of the Center that will be pursued in this 5 year renewal include: 1) mechanisms of addiction and identification of novel targets with therapeutic potential; 2) effects of drugs of abuse on HIV infection; 3) neuroimmune interactions, including cross-talk between classical neurotransmitter systems and chemokines/cytokines as related to addiction, pain, inflammation and HIV; 4) pain and analgesia with the goal of identifying opioid-sparing treatments for pain. Research is carried out on a broad spectrum of substances including opioids, cannabinoids, psychostimulants, nicotine and alcohol. The Center consists of five Research Support Cores: The Animal Core for Addiction Related Behaviors, Biochemical Pharmacology Core, Cell and Immunology Core, Integrated Physiological Systems and Pain Core, and the Molecular Biology Core, in addition to the Administrative and Pilot Project Cores. The Core personnel bring to the Center a broad array of expertise to address scientific questions related to drugs of abuse, addiction, pain and HIV from multiple approaches leading to research synergy. This unique aspect of the P30 Center at Temple encourages collaborations that extend beyond a single discipline to address novel hypotheses and significantly accelerate the progress of individual research programs. Implementation of several new state-of-the-art approaches are proposed in this renewal application that will add major strengths to the Center. The NIDA P30 Core Center will provide cutting-edge technologies to expand the impact of NIH-funded research projects related to NIDA's mission through collaborations nation-wide. In addition, research training and mentoring of early career scientists will continue to be an important function. The Center will serve as a national resource to stimulate innovative scientific discoveries that will result in new knowledge to bear on substance abuse.

Public Health Relevance

Substance abuse and addiction continue to be major public health problems with enormous personal, society, and public health costs. The goal of the NIDA P30 Center at Temple University is to support high quality, innovative research on drugs of abuse, addiction, HIV, and pain. The Core facilities will provide state-of-the-art resources and expertise to enhance and expand the scope of research in the field, to promote research synergy, and provide training for future generations of researchers.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Tsai, Shang-Yi Anne
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Temple University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Simmons, Steven J; Gregg, Ryan A; Tran, Fionya H et al. (2018) Comparing rewarding and reinforcing properties between 'bath salt' 3,4-methylenedioxypyrovalerone (MDPV) and cocaine using ultrasonic vocalizations in rats. Addict Biol 23:102-110
Hill, Jeremy D; Zuluaga-Ramirez, Viviana; Gajghate, Sachin et al. (2018) Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis. Br J Pharmacol :
Cotto, Bianca; Li, Hongbo; Tuma, Ronald F et al. (2018) Cocaine-mediated activation of microglia and microglial MeCP2 and BDNF production. Neurobiol Dis 117:28-41
Ward, Sara Jane; Castelli, Francesca; Reichenbach, Zachary W et al. (2018) Surprising outcomes in cannabinoid CB1/CB2 receptor double knockout mice in two models of ischemia. Life Sci 195:1-5
Liu, Jeffrey J; Sharma, Kirti; Zangrandi, Luca et al. (2018) In vivo brain GPCR signaling elucidated by phosphoproteomics. Science 360:
Oliver, Chicora F; Simmons, Steven J; Nayak, Sunil U et al. (2018) Chemokines and 'bath salts': CXCR4 receptor antagonist reduces rewarding and locomotor-stimulant effects of the designer cathinone MDPV in rats. Drug Alcohol Depend 186:75-79
Zewde, Ashenafi Mebratu; Yu, Frances; Nayak, Sunil et al. (2018) PLDT (planarian light/dark test): an invertebrate assay to quantify defensive responding and study anxiety-like effects. J Neurosci Methods 293:284-288
Rom, Slava; Zuluaga-Ramirez, Viviana; Reichenbach, Nancy L et al. (2018) Secoisolariciresinol diglucoside is a blood-brain barrier protective and anti-inflammatory agent: implications for neuroinflammation. J Neuroinflammation 15:25
Ramirez, Servio H; Andrews, Allison M; Paul, Debayon et al. (2018) Extracellular vesicles: mediators and biomarkers of pathology along CNS barriers. Fluids Barriers CNS 15:19
Brailoiu, Eugen; Barlow, Christine L; Ramirez, Servio H et al. (2018) Effects of Platelet-Activating Factor on Brain Microvascular Endothelial Cells. Neuroscience 377:105-113

Showing the most recent 10 out of 343 publications